Earnings Report·May 6, 2026
ARQT Q1 2026: ZORYVE Revenue Hits $105.4M, Up 65% YoY as EPS Misses Estimate
Arcutis Biotherapeutics posted strong ZORYVE revenue growth of 65% YoY in Q1 2026, though EPS of $(0.09) fell short of the $(0.06) consensus.
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Stock News & Analysis
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on ARQT since May 6, 2026, most recently "FDA Approves ZORYVE Cream 0.3% for Plaque Psoriasis in Children as Young as 2 (ARQT)" on Wednesday, July 1, 2026. Coverage to date spans Health Care and Earnings Report, tracking ARQT's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
ARQT Coverage -- 2 Articles
Health Care·Wednesday, July 1, 2026
FDA Approves ZORYVE Cream 0.3% for Plaque Psoriasis in Children as Young as 2 (ARQT)
ZORYVE cream 0.3% becomes the first once-daily, non-steroidal therapy cleared for plaque psoriasis in children as young as 2, expanding Arcutis' label.
3 min readRead article
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.